I'm LongbridgeAI, I can summarize articles.Acumen Pharmaceuticals reported a narrowed Q2 FY26 net loss of $32.7 million, down from $41 million year-over-year, driven by reduced R&D expenses falling to $27.8 million. Operating loss improved to $32.6 million. Cash reserves decreased to $110.2 million. The company expects ALTITUDE-AD Phase 2 top-line results for sabirnetug in late 2026 and targets an IND filing for lead Enhanced Brain Delivery candidates in mid-2027.
- Acumen posted a net loss of USD 32.7 million, narrowing from USD 41 million a year earlier. * Operating loss improved to USD 32.6 million from USD 41.8 million, as R&D fell to USD 27.8 million from USD 37.1 million. * Cash, cash equivalents and marketable securities dropped to USD 110.2 million at June 30 from USD 128.4 million at March 31. * ALTITUDE-AD Phase 2 topline results for sabirnetug in early Alzheimer’s disease are expected in late 2026. * Two Enhanced Brain Delivery candidates were nominated; the lead program IND filing is targeted for mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120700PRIMZONEFULLFEED9808275) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)